Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus.
The emergence and spread of multidrug-resistant gram-positive bacteria represent a serious clinical problem. Telavancin is a novel lipoglycopeptide antibiotic that possesses rapid in vitro bactericidal activity against a broad spectrum of clinically relevant gram-positive pathogens. Here we demonstrate that telavancin's antibacterial activity derives from at least two mechanisms. As observed with vancomycin, telavancin inhibited late-stage peptidoglycan biosynthesis in a substrate-dependent fashion and bound the cell wall, as it did the lipid II surrogate tripeptide N,N'-diacetyl-L-lysinyl-D-alanyl-D-alanine, with high affinity. Telavancin also perturbed bacterial cell membrane potential and permeability. In methicillin-resistant Staphylococcus aureus, telavancin caused rapid, concentration-dependent depolarization of the plasma membrane, increases in permeability, and leakage of cellular ATP and K(+). The timing of these changes correlated with rapid , concentration-dependent loss of bacterial viability, suggesting that the early bactericidal activity of telavancin results from dissipation of cell membrane potential and an increase in membrane permeability. Binding and cell fractionation studies provided direct evidence for an interaction of telavancin with the bacterial cell membrane; stronger binding interactions were observed with the bacterial cell wall and cell membrane relative to vancomycin. We suggest that this multifunctional mechanism of action confers advantageous antibacterial properties.
Higgins
Deborah L
DL
Theravance, Inc., 901 Gateway Blvd., South San Francisco, CA 94080, USA.
Chang
Ray
R
Debabov
Dmitri V
DV
Leung
Joey
J
Wu
Terry
T
Krause
Kevin M
KM
Sandvik
Erik
E
Hubbard
Jeffrey M
JM
Kaniga
Koné
K
Schmidt
Donald E
DE
Gao
Qiufeng
Q
Cass
Robert T
RT
Karr
Dane E
DE
Benton
Bret M
BM
Humphrey
Patrick P
PP
D000617:Aminoglycosides / Q000494:pharmacology*; D002462:Cell Membrane / Q000187:drug effects*; D002473:Cell Wall / Q000187:drug effects* / Q000378:metabolism; D000077427:Lipoglycopeptides; D016106:Methicillin Resistance; D010457:Peptidoglycan / Q000096:biosynthesis; D013211:Staphylococcus aureus / Q000187:drug effects*
D000617:Aminoglycosides; D000077427:Lipoglycopeptides; D010457:Peptidoglycan; C487637:telavancin
J Antibiot (Tokyo). 1989 Jan;42(1):63-72
2921228
Science. 1999 Dec 17;286(5448):2361-4
10600751
Eur J Clin Microbiol Infect Dis. 1989 Nov;8(11):943-50
2532132
FEMS Microbiol Lett. 1991 Mar 1;62(2-3):253-7
1904044
J Med Chem. 1993 Jan 8;36(1):126-33
8421278
Chem Biol. 1999 Dec;6(12):891-9
10631517
FEMS Microbiol Lett. 2000 Feb 15;183(2):209-14
10675585
FEMS Microbiol Lett. 2000 Oct 15;191(2):187-90
11024262
Microbiology. 2000 Dec;146 Pt 12:3129-40
11101671
Appl Environ Microbiol. 2001 Sep;67(9):4264-71
11526032
Curr Med Chem. 2001 Dec;8(14):1759-73
11562292
Chem Biol. 2001 Nov;8(11):1095-106
11731300
J Med Chem. 2002 Mar 14;45(6):1340-7
11882003
Antimicrob Agents Chemother. 2002 Aug;46(8):2344-8
12121903
MMWR Morb Mortal Wkly Rep. 2002 Jul 5;51(26):565-7
12139181
J Antimicrob Chemother. 2002 Nov;50(5):731-4
12407132
Appl Environ Microbiol. 2003 Feb;69(2):1305-7
12571063
FEMS Microbiol Rev. 2003 Jan;26(5):511-32
12586393
Chemistry. 2003 Apr 4;9(7):1556-65
12658654
Proc Natl Acad Sci U S A. 2003 May 13;100(10):5658-63
12714684
Antimicrob Agents Chemother. 2003 Aug;47(8):2538-44
12878516
Antimicrob Agents Chemother. 2003 Nov;47(11):3602-4
14576125
Bioorg Med Chem Lett. 2003 Dec 1;13(23):4165-8
14622994
J Antimicrob Chemother. 2004 May;53(5):797-803
15028667
Antimicrob Agents Chemother. 2004 Jun;48(6):2149-52
15155214
Chem Biol. 2004 Jul;11(7):949-57
15271353
Antimicrob Agents Chemother. 2004 Aug;48(8):3043-50
15273119
J Antibiot (Tokyo). 2004 May;57(5):326-36
15303493
Biochem J. 1971 Aug;123(5):773-87
5124385
Biochem J. 1972 Jan;126(1):139-49
4627581
Annu Rev Microbiol. 1984;38:339-57
6388496
Antimicrob Agents Chemother. 1987 Jul;31(7):1014-6
2821883
Anal Biochem. 1987 Aug 15;165(1):108-13
3688425
Biochem Pharmacol. 1988 Jan 1;37(1):133-41
3276316
J Antibiot (Tokyo). 1995 Aug;48(8):805-10
7592024
Antimicrob Agents Chemother. 1995 Nov;39(11):2585-7
8585753
J Antibiot (Tokyo). 1996 Jun;49(6):575-81
8698642
Antimicrob Agents Chemother. 1996 Sep;40(9):2194-9
8878606
Antimicrob Agents Chemother. 1996 Oct;40(10):2356-62
8891144
Antimicrob Agents Chemother. 1996 Oct;40(10):2416-9
8891155
Chem Biol. 1996 Jan;3(1):21-8
8807824
Med Res Rev. 1997 Jan;17(1):69-137
8979249
Antimicrob Agents Chemother. 1997 Jan;41(1):66-71
8980756
J Antibiot (Tokyo). 1997 Aug;50(8):677-84
9315081
J Clin Invest. 1998 Jan 1;101(1):178-87
9421480
Electrophoresis. 1998 Mar;19(3):367-82
9551788
Science. 1999 Apr 16;284(5413):507-11
10205063
Antimicrob Agents Chemother. 1999 May;43(5):1111-7
10223922
Biochemistry. 1999 Jun 1;38(22):7235-42
10353835
Can J Biochem Physiol. 1959 Aug;37(8):911-7
13671378
Antimicrob Agents Chemother. 1995 Mar;39(3):781-5
7793894
Genetics. 1989 Jul;122(3):491-501
2547691